NCT07042620 2026-04-16
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
SonoClear AS
Phase NA Recruiting
Clinical Trials
1,779 trialsNCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT07416188 2026-04-16
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
NCT03451799 2026-04-15
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Completed
NCT04762069 2026-04-15
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT06325683 2026-04-15
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT06641908 2026-04-15
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono
Phase 1 Recruiting
NCT01507506 2026-04-14
SPECTRO GLIO
Institut Claudius Regaud
Phase 3 Terminated
NCT01872221 2026-04-14
STEMRI
Institut Claudius Regaud
Phase NA Completed
NCT02866747 2026-04-14
STERIMGLI
Institut Claudius Regaud
Phase 1/2 Completed
NCT06512311 2026-04-14
ATTRACT
Medical University of Vienna
Phase NA Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT06805305 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
NCT07185880 2026-04-14
STAR-GBM
Myosin Therapeutics Inc.
Phase 1/2 Recruiting
NCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT00268385 2026-04-13
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02152982 2026-04-13
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT02800486 2026-04-13
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Phase 2 Recruiting
NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03911388 2026-04-13
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03919071 2026-04-13
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04145115 2026-04-13
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04528680 2026-04-13
SC9/ABX
Northwestern University
Phase 1/2 Active not recruiting
NCT04988750 2026-04-13
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
NaviFUS Corporation
Phase NA Completed
NCT05168423 2026-04-13
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
University of Pennsylvania
Phase 1 Active not recruiting
NCT05432804 2026-04-13
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Suspended
NCT06419946 2026-04-13
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06860594 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07422363 2026-04-13
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT07521657 2026-04-13
NF118
University of Alabama at Birmingham
Phase 2 Not yet recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT03277638 2026-04-09
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Case Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT04730869 2026-04-09
Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma
Waikato Hospital
Phase NA Completed
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06344130 2026-04-09
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT07134842 2026-04-09
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT03970447 2026-04-08
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT06129760 2026-04-08
Glioblastoma Remote Monitoring and Care - Research Protocol
Case Comprehensive Cancer Center
Phase NA Suspended
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT07512154 2026-04-07
Precision Radiotherapy Enabled by Molecular MRI
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Not yet recruiting
NCT07515924 2026-04-07
Oral Gallium Maltolate for Recurrent Glioblastoma
Medical College of Wisconsin
Phase EARLY_PHASE1 Not yet recruiting
NCT04978727 2026-04-06
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 1 Active not recruiting
NCT06910306 2026-04-06
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT07488754 2026-04-06
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
Medical University of Warsaw
Phase NA Recruiting